Although they were used initially as non-specific immunosuppressants in transplantation,
CD3-specific monoclonal antibodies have elicited renewed interest owing to their capacity to …

The first CD52 Abs were isolated in 1980 during a search for Abs that could kill lymphocytes
by activating human complement [1]. This was motivated by the thought that they should be …

Novel methods for producing, and compositions of, humanized immunoglobulins having one
or more complementarity determining regions (CDR's) and possible additional amino acids …

Background Type 1 diabetes mellitus is a T-cell–mediated autoimmune disease that leads to
a major loss of insulin-secreting beta cells. The further decline of beta-cell function after …

Abstract The Fc variant of IgG2, designated as IgG2σ, was engineered with
V234A/G237A/P238S/H268A/V309L/A330S/P331S substitutions to eliminate affinity for Fcγ …

CD3 antibodies are proven immunosuppressants capable of reversing transplant rejection
episodes. Their general application has been limited both by their immunogenicity and, in …

FR2844513A1 (en)* 2002-09-13 2004-03-19 Lab Francais Du Fractionnement Chimeric or
human monoclonal antibody, useful for treating eg cancer and infections, is selected for high …

The binding specificity of the murine OKT3 has been transferred into a human antibody
framework in order to reduce its immunogenicity.'Humanized'anti-CD3 mAbs, such as …

We report here the humanization of a mouse monoclonal antibody (mAb B233) using a new
technique which we call framework shuffling. mAb B233 was raised against the human …

Background. The potential therapeutic benefits of CD3 monoclonal antibodies, such as
OKT3, have been limited by their immunogenicity and their propensity to activate a severe …